Recombinant Anti-PD-L1 antibody [SP142] - C-terminal (ab228462)

Publishing research using ab228462? Please let us know so that we can cite the reference in this datasheet.

ab228462 has been referenced in 65 publications.

  • Chen XJ  et al. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. Pathol Res Pract N/A:152418 (2019). PubMed: 31027907
  • Dill EA  et al. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod Pathol N/A:N/A (2018). PubMed: 29802358
  • Arias-Pulido H  et al. The combined presence of CD20?+?B cells and PD-L1?+?tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat N/A:N/A (2018). PubMed: 29858752
  • Miyamoto E  et al. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. J Surg Oncol 117:1405-1412 (2018). IHC ; Human . PubMed: 29663398
  • Toyokawa G  et al. Computed tomography features of resected lung adenocarcinomas with spread through air spaces. J Thorac Cardiovasc Surg 156:1670-1676.e4 (2018). PubMed: 29961590
  • Suster D  et al. Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus. Mod Pathol N/A:N/A (2018). PubMed: 29973653
  • Wang C  et al. Immune profiling of microsatellite instability-high and polymerase e (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol 9:404-415 (2018). IHC-P ; Human . PubMed: 29998005
  • Kozuma Y  et al. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. Eur J Cancer 101:20-29 (2018). PubMed: 30014971
  • Halse H  et al. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. Sci Rep 8:11158 (2018). PubMed: 30042403
  • Pratt D  et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery N/A:N/A (2018). IHC-P . PubMed: 30011045
  • Tomioka N  et al. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer 25:34-42 (2018). PubMed: 28488168
  • Hirai A  et al. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. J Thorac Cardiovasc Surg 155:382-392.e1 (2018). PubMed: 28711324
  • Takamori S  et al. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review. Clin Lung Cancer 19:12-16 (2018). PubMed: 28739315
  • Harada K  et al. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer 21:31-40 (2018). PubMed: 28801853
  • Ahn J  et al. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. Laryngoscope 128:E27-E32 (2018). PubMed: 28940446
  • Korehisa S  et al. A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer. Histopathology 72:697-703 (2018). PubMed: 28940664
  • Korehisa S  et al. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Int J Cancer 142:822-832 (2018). PubMed: 29044503
  • Dong ZY  et al. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. J Thorac Oncol 13:85-96 (2018). PubMed: 29127022
  • Haratake N  et al. Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer. Ann Thorac Surg 105:448-454 (2018). PubMed: 29254651
  • Daroontum T  et al. Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan. Histopathology N/A:N/A (2018). PubMed: 29314151
  • Eroglu Z  et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350 (2018). PubMed: 29320474
  • Sakakibara A  et al. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. Histopathology N/A:N/A (2018). PubMed: 29380399
  • Zheng B  et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol 11:16 (2018). PubMed: 29409495
  • Takada K  et al. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer 116:1-6 (2018). PubMed: 29413045
  • Kwa MJ & Adams S Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer N/A:N/A (2018). PubMed: 29424936
  • Wang S  et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol N/A:N/A (2018). PubMed: 29427150
  • Keller MD  et al. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. Mod Pathol 31:101-110 (2018). PubMed: 28884747
  • Takada K  et al. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Clin Lung Cancer 19:120-129 (2018). PubMed: 29153898
  • Le Flahec G  et al. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Hum Pathol 72:135-143 (2018). PubMed: 29208565
  • Tseng YH  et al. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. J Thorac Oncol 13:447-453 (2018). PubMed: 29246835
  • Chen Z  et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol 11:20 (2018). PubMed: 29433585
  • Vanderwalde A  et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7:746-756 (2018). PubMed: 29436178
  • Toyokawa G  et al. Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma. Ann Thorac Surg N/A:N/A (2018). PubMed: 29453963
  • Monneur A  et al. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. Bull Cancer 105:263-274 (2018). PubMed: 29455872
  • Okamoto T  et al. Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. Ann Surg Oncol N/A:N/A (2018). PubMed: 29500766
  • Wu SP  et al. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. J Thorac Oncol 13:521-532 (2018). PubMed: 29269008
  • Takashima Y  et al. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clin Lung Cancer N/A:N/A (2018). PubMed: 29544718
  • Akamine T  et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Surg Oncol 27:88-94 (2018). PubMed: 29549910
  • Mills A  et al. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol N/A:N/A (2018). PubMed: 29559741
  • Ojalvo LS  et al. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Hum Pathol 74:135-147 (2018). PubMed: 29288043
  • Rojkó L  et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. J Cancer Res Clin Oncol N/A:N/A (2018). Human . PubMed: 29675791
  • Owen D  et al. Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. J Thorac Oncol N/A:N/A (2018). Human . PubMed: 29702286
  • Toyokawa G  et al. Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis. Clin Lung Cancer N/A:N/A (2018). PubMed: 29735272
  • Parra ER  et al. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93 (2018). PubMed: 28719380
  • Wang L  et al. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Hum Pathol 71:20-29 (2018). PubMed: 28782638
  • Scognamiglio T & Chen YT Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. Head Neck Pathol N/A:N/A (2017). PubMed: 28948509
  • Shao L  et al. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag Res 9:249-258 (2017). PubMed: 28721097
  • Thompson ED  et al. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Mod Pathol 30:1551-1560 (2017). PubMed: 28731046
  • Joneja U  et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol 70:255-259 (2017). PubMed: 27531819
  • Jin S  et al. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Oncotarget 8:38850-38862 (2017). PubMed: 28418918
  • Lai AZ  et al. Detection of anALKFusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist 22:774-779 (2017). PubMed: 28507204
  • Alvi MA  et al. Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer 117:203-209 (2017). PubMed: 28595259
  • Imai D  et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 6:1614-1626 (2017). PubMed: 28602029
  • Reddy OL  et al. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol 12:45 (2017). PubMed: 28623908
  • Colombo C  et al. ß-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Mol Oncol 11:1495-1507 (2017). PubMed: 28627792
  • Momose K  et al. MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. Oncol Lett 14:958-964 (2017). PubMed: 28693258
  • Falchook GS  et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer 4:70 (2016). PubMed: 27879972
  • Scheel AH  et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29:1165-72 (2016). IHC ; Human . PubMed: 27389313
  • McDermott DF  et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol 34:833-42 (2016). PubMed: 26755520
  • Melosky B  et al. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. J Clin Oncol 34:1676-88 (2016). PubMed: 26884577
  • Ilie M  et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 468:511-25 (2016). PubMed: 26915032
  • Shi L  et al. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res 22:1173-1184 (2016). PubMed: 26933175
  • Böhm S  et al. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. Clin Cancer Res 22:3025-36 (2016). PubMed: 27306793
  • Garber ST  et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18:1357-66 (2016). PubMed: 27370400
  • Vieira T  et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 98:51-58 (2016). PubMed: 27393506

For licensing inquiries, please contact

Sign up